MarketCap
Facebook
X
TelegramAnnual report 2025
added 03-30-2026
Precipio Market Cap 2011-2026 | PRPO
As of May 01, 2026 Precipio has a market cap of $ 49.6 M
Capitalization is the market value of a company whose shares are traded on the stock exchange. It is calculated by multiplying the market price of a share by the total number of the company's shares. Capitalization indicates volatility, risk, and growth potential. This metric is often used for a quick assessment of a company’s investment profile.[1]
Capitalization is an important indicator for investors and analysts, as it helps determine the size and significance of a company in the stock market. Companies with large capitalization are considered more stable and reliable, as they have more resources and financial power to grow and survive in the market.
This metric can be divided into several categories: small (from 300 million to 2 billion dollars), medium (from 2 to 10 billion dollars), and large (over 10 billion dollars). Companies with different levels of capitalization have their own characteristics and risks, so investors usually take this indicator into account when making investment decisions.
Capitalization can also change over time depending on the share price and the number of shares in circulation. Therefore, it is a dynamic indicator that requires constant monitoring and analysis to make well-informed investment decisions.
Annual Market Cap Precipio
| 2025 | 2024 | 2023 | 2022 | 2021 | 2020 | 2019 | 2018 | 2017 | 2016 | 2015 | 2014 | 2013 | 2012 | 2011 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 38.4 M | 35 M | 8.7 M | 774 K | 32.3 M | 45.5 M | 11 M | 4.22 M | 5.34 M | 16.1 M | 7.89 M | 28 M | - | - | - |
All numbers in USD currency
Indicator range from annual reports
| Maximum | Minimum | Average |
|---|---|---|
| 45.5 M | 774 K | 19.4 M |
References
- Pavone, P. (2019). Market capitalization and financial variables: Evidence from Italian listed companies. International Journal of Academic Research Business and Social Sciences, 9(3), 1356-1371.
Market Cap of other stocks in the Diagnostics research industry
| Issuer | Market Cap | Price | % 24h | Market Cap | Country | |
|---|---|---|---|---|---|---|
 |
Centogene N.V.
CNTG
|
221 M | - | -6.23 % | $ 30.6 M |  Germany |
 |
Accelerate Diagnostics
AXDX
|
40.3 M | - | -61.36 % | $ 2.46 M |  USA |
 |
Agilent Technologies
A
|
42 B | $ 115.55 | 3.81 % | $ 35.1 B | USA |
 |
CareDx, Inc
CDNA
|
993 M | $ 20.81 | 0.05 % | $ 1.11 B | USA |
 |
Co-Diagnostics
CODX
|
5.85 M | $ 1.55 | 1.31 % | $ 2.06 M | USA |
 |
Castle Biosciences
CSTL
|
709 M | $ 24.49 | 1.03 % | $ 680 M | USA |
|
Akumin
AKU
|
75.1 M | - | -17.87 % | $ 25.9 M |  Canada |
 |
Biocept
BIOC
|
5.93 M | - | -13.05 % | $ 7.29 M | USA |
 |
Fulgent Genetics
FLGT
|
467 M | $ 15.19 | 2.64 % | $ 459 M | USA |
 |
Aspira Women's Health
AWH
|
45.4 M | - | -6.19 % | $ 10.5 M | USA |
 |
Chembio Diagnostics
CEMI
|
12.6 M | - | 0.22 % | $ 16.8 M | USA |
 |
Oxford Immunotec Global PLC
OXFD
|
421 M | - | - | $ 562 M |  Britain |
 |
Check-Cap Ltd.
CHEK
|
4.33 M | - | - | $ 9.42 M |  Israel |
 |
Heska Corporation
HSKA
|
844 M | - | - | $ 1.31 B | USA |
 |
HTG Molecular Diagnostics
HTGM
|
2.99 M | - | -20.0 % | $ 1.06 M | USA |
 |
ICON Public Limited Company
ICLR
|
16.6 B | $ 118.33 | 1.86 % | $ 9.76 B |  Irlanda |
 |
Illumina
ILMN
|
16.4 B | $ 126.74 | 5.29 % | $ 20.2 B | USA |
 |
DermTech
DMTK
|
42.4 M | - | -11.32 % | $ 2.94 M | USA |
 |
Global Cord Blood Corporation
CO
|
243 M | - | - | $ 399 M |  China |
 |
Fluidigm Corporation
FLDM
|
481 M | - | 1.08 % | $ 308 M | USA |
 |
Genetic Technologies Limited
GENE
|
9.22 B | - | - | $ 7.1 B |  Australia |
 |
Genetron Holdings Limited
GTH
|
1.54 B | - | 0.12 % | $ 80.1 M | China |
 |
Charles River Laboratories International
CRL
|
7.69 B | $ 166.97 | 1.91 % | $ 8.28 B | USA |
 |
PRA Health Sciences, Inc.
PRAH
|
7.87 B | - | - | $ 10.7 B | USA |
 |
Lantheus Holdings
LNTH
|
5.12 B | $ 84.62 | 4.25 % | $ 5.71 B | USA |
 |
Enzo Biochem
ENZ
|
57.5 K | - | -8.98 % | $ 14.8 K | USA |
 |
Exact Sciences Corporation
EXAS
|
19.5 B | - | - | $ 19.8 B | USA |
 |
Medpace Holdings
MEDP
|
13 B | $ 418.66 | 1.23 % | $ 12.1 B | USA |
 |
Guardant Health
GH
|
13.4 B | $ 87.08 | 4.4 % | $ 10.9 B | USA |
 |
Motus GI Holdings
MOTS
|
990 K | - | -34.28 % | $ 263 K | Israel |
 |
Koninklijke Philips N.V.
PHG
|
30.8 B | $ 26.34 | 2.95 % | $ 20 B |  Niderland |
 |
Myriad Genetics
MYGN
|
409 M | $ 4.75 | 1.5 % | $ 440 M | USA |
 |
Interpace Biosciences
IDXG
|
7.34 M | $ 1.98 | -0.5 % | $ 8.76 M | USA |
 |
NeoGenomics
NEO
|
1.48 B | $ 9.26 | 3.35 % | $ 1.19 B | USA |
 |
QIAGEN N.V.
QGEN
|
8.52 B | - | - | $ 10.6 B | Niderland |
 |
Biomerica
BMRA
|
7.19 M | $ 2.18 | 0.93 % | $ 5.01 M | USA |
 |
Laboratory Corporation of America Holdings
LH
|
23.9 B | $ 256.8 | -0.13 % | $ 21.4 B | USA |
 |
National Research Corporation
NRC
|
315 M | $ 16.46 | -0.48 % | $ 368 M | USA |
 |
Celcuity
CELC
|
5.37 B | $ 121.35 | 1.97 % | $ 5.67 B | USA |
 |
Natera
NTRA
|
5.31 B | $ 206.16 | 5.86 % | $ 20.3 B | USA |
 |
Neogen Corporation
NEOG
|
1.02 B | $ 9.4 | 4.33 % | $ 2.04 B | USA |
 |
Invitae Corporation
NVTA
|
511 M | - | - | $ 21.2 M | USA |
 |
Quest Diagnostics Incorporated
DGX
|
23.3 B | $ 194.2 | 2.58 % | $ 21.6 B | USA |
 |
OpGen
OPGN
|
9.12 M | - | -16.95 % | $ 1.54 M | USA |
 |
Organovo Holdings
ONVO
|
3.1 M | - | -2.3 % | $ 19.4 M | USA |
 |
PerkinElmer
PKI
|
14.1 B | - | -0.91 % | $ 14.7 B | USA |
 |
Exagen
XGN
|
70.1 M | $ 2.9 | 5.07 % | $ 62.5 M | USA |
 |
Burning Rock Biotech Limited
BNR
|
2.95 B | $ 17.0 | 4.68 % | $ 179 M | China |
 |
Personalis
PSNL
|
254 M | $ 5.52 | 9.52 % | $ 327 M | USA |